Figure 5.

A, Radiolabeling of PBR in brains of mice without treatment (Control) and treated with CZ. The corpus callosum (CC) and striatum (ST) are outlined by dots. B–E, Immunofluorescence staining of GFAP (B, D) and Iba-1 (C, E) in brain sections of untreated (B, C) and CZ-treated (D, E) mice. Dashed lines define borders of CC and ST. F–H, Double immunofluorescence labeling of MBP and Iba-1 (F), MBP and GFAP (G), and PBR (NP155) and GFAP (H) in striatal sections of a CZ-treated mouse. Arrowheads in H indicate astrocytes doubly positive for PBR and GFAP. I–K, In vivo detection of PBR in CZ-treated mice. Coronal (1 mm anterior to the bregma) PET images in control (I) and CZ-treated (J) mice were generated by summation of dynamic data at 0–60 min after injection of [¹⁸F]FE-DAA1106 and were overlaid on the MRI template. Marked increase of radioactivity was found primarily in the corpus callosum and striatum (arrows). Time-radioactivity curves (K) for striatal VOIs in control (open circles) and CZ-fed (closed circles) mice indicate ∼2-fold increase of radioligand accumulation induced by CZ treatment. Scale bars: (A) 2 mm, (B–E) 150 μm, (F–H) 25 μm.